Oxford Immunotec (UK) and Becton, Dickinson and Company (US) are Leading Players in the ELISpot and FluoroSpot Assay Market
The global ELISpot and FluoroSpot Assays Market is expected to reach USD 390 million by 2027 from USD 274 million in 2022, at a CAGR of 7.3% during the forecast period. The growth of this market is majorly driven by Increasing vaccine development to address challenges of antimicrobial resistance. However, Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables is one of the challenges for which may hinder the growth of this market.
The key players operating in this market are Oxford Immunotec (UK), Cellular Technology Limited (US), Mabtech (Sweden), Becton, Dickinson and Company (US), Abcam plc.(UK), Bio-Techne.(US), Mikrogen Diagnostik (Germany), Autoimmun Diagnostika GmbH (Germany), U-CyTech (Netherland), and Medix Biochemica (Finland)
To know about the assumptions considered for the study download the pdf brochure
Oxford Immunotec (UK)
Oxford Immunotec is among the top players in the ELISpot and FluoroSpot assays market. It is focused on the development of diagnostic kits for infectious diseases, tick-borne diseases, and transplant-related infections. The company offers assay kits as well as testing services to its end users. ELISpot and FluoroSpot assay diagnostic kits offer a competitive edge over other competing technologies, such as ELISA with higher sensitivity and single-cell qualitative and quantitative detection. The company has an extensive product portfolio based on various technologies. It has a strong presence across North America, Europe, Asia, and the Middle East, alongside a strong direct and indirect distribution network across the globe. With the increasing use of ELISpot kits for diagnosis, Oxford Immunotec is expected to maintain its leading position in the ELISpot and FluoroSpot assays market during the forecast period.
Becton, Dickinson and Company (US)
BD is involved in the development and supply of a wide range of life sciences and biotechnology products. The company has a strong product portfolio, and its FDA- and CE-approved products have helped it gain a sizable share of the EliSpot and FluoroSpot assays market. The company has made progress by shifting its portfolio into higher-growth spaces by reallocating the R&D spending. It invested USD 1,339 million, USD 1,096 million, and 1,062 million in 2021, 2020, and 2019, respectively, on R&D. The company’s products are sold to a geographically diverse customer base. The company continues to improve its global supply chain, which helps ensure continued access to its products. This is expected to help the company retain its position in the market. Also, it is strengthening its long-term targeted growth profile through a series of decisions, such as increasing organic innovation, geographic expansions, and M&A to drive growth.
Related Reports:
ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplants, Vaccine Development), End User (Hospitals & Clinical Labs, Research Institutes) - Global Forecast to 2027
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
